Precision Medicine Using Pharmacogenomic Panel-Testing: Current Status and Future Perspectives

Clin Lab Med. 2022 Dec;42(4):587-602. doi: 10.1016/j.cll.2022.09.012.

Authors

Cathelijne H van der Wouden¹, Henk-Jan Guchelaar¹, Jesse J Swen²

Affiliations

¹ Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, The Netherlands; Leiden Network for Personalised Therapeutics, Leiden, The Netherlands.
² Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Albinusdreef 2, Leiden 2333ZA, The Netherlands; Leiden Network for Personalised Therapeutics, Leiden, The Netherlands. Electronic address: j.j.swen@lumc.nl.

PMID: 36368784
DOI: 10.1016/j.cll.2022.09.012

No abstract available

Keywords: Adverse drug reactions; Implementation; Panel-testing; Pharmacogenomics.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Pharmacogenetics*
Precision Medicine*